Evidence map›Paper›PMID 24667631›Full record

ArticlePloS one2014

The effects of super-flux (high performance) dialyzer on plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-Terminal proBNP in end-stage renal disease patients on dialysis.

Yasuaki Nakagawa, Toshio Nishikimi, Koichiro Kuwahara, Shinji Yasuno, Hideyuki Kinoshita, Yoshihiro Kuwabara, Kazuhiro Nakao, Takeya Minami, Chinatsu Yamada, Kenji Ueshima and 7 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Yasuaki NakagawaDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Toshio NishikimiDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Koichiro KuwaharaDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Shinji YasunoDepartment of EBM Research, Kyoto University Hospital, Institute for Advancement of Clinical and Translational Science, Kyoto, Japan.
Hideyuki KinoshitaDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yoshihiro KuwabaraDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kazuhiro NakaoDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takeya MinamiDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Chinatsu YamadaDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kenji UeshimaDepartment of EBM Research, Kyoto University Hospital, Institute for Advancement of Clinical and Translational Science, Kyoto, Japan.
Yoshihiro IkedaMedical corporation, Ikeda Clinic, Kyoto, Japan.
Hiroyuki OkamotoDiagnostics Division, Shionogi & Co., Ltd, Oska, Japan.
Kazukiyo HoriiDiagnostics Division, Shionogi & Co., Ltd, Oska, Japan.
Kiyoshi NagataDiagnostics Division, Shionogi & Co., Ltd, Oska, Japan.
Kenji KangawaDepartment of Biochemistry, National Cerebral and Cardiovascular Center Research Institute, Fujishirodai, Suita, Osaka, Japan.
Naoto MinaminoDepartment of Molecular Pharmacology, National Cerebral and Cardiovascular Center Research Institute, Fujishirodai, Suita, Osaka, Japan.
Kazuwa NakaoDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kyoto University · JPKyoto University Hospital · JPNational Cerebral and Cardiovascular Center · JPShionogi (Japan) · JPFutaba (Japan) · JPKyoto Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasma BNP levels are predictive of prognosis in hemodialysis patients. However, recent studies showed that the current BNP immunoassay cross-reacts with glycosylated proBNP, and the NT-proBNP assay underestimates glycosylated NT-proBNP. In addition, the recently developed high performance dialyzer removes medium-sized molecular solutes such as β2-microgloburin. We therefore investigated the effects of high performance dialysis on measured levels of glycosylated proBNP, glycosylated NT-proBNP and other BNP-related peptides in end-stage renal disease (ESRD) patients on hemodialysis.

methodThe relationships between clinical parameters and BNP-related molecule were also investigated. We used our newly developed immunoassay to measure plasma total BNP and proBNP in 105 normal subjects and 36 ESRD patients before and after hemodialysis. Plasma NT-proBNP was measured using Elecsys II after treatment with or without deglycosylating enzymes. We also measured plasma ANP and cGMP using radioimmunoassays.

resultsAll the measured BNP-related peptides were significantly higher in ESRD patients than healthy subjects. Total BNP (-38.9%), proBNP (-29.7%), glycoNT-proBNP (-45.5%), nonglycoNT-proBNP (-53.4%), ANP (-50.4%) and cGMP (-72.1%) were all significantly reduced after hemodialysis, and the magnitude of the reduction appeared molecular weight- dependent. Both the proBNP/total BNP and glycoNT-proBNP/nonglycoNT-proBNP ratios were increased after hemodialysis. The former correlated positively with hemodialysis vintage and negatively with systolic blood pressure, while the latter correlated positively with parathyroid hormone levels.

conclusionThese results suggest that hemodialysis using super-flux dialyzer removes BNP-related peptides in a nearly molecular weight-dependent manner. The ProBNP/total BNP and glycoNT-proBNP/nonglycoNT-proBNP ratios appear to be influenced by hemodialysis-related parameters in ESRD patients on hemodialysis.

Indexed as

Fluid TherapyAgedCase-Control StudiesEchocardiographyFemaleGlycosylationHumansKidney Failure, ChronicMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisRenal DialysisNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID24667631
PMCPMC3965412
OpenAlexW2782713151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.